1383377-50-1

Basic information

• Product Name: 3-fluoro-4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-picolinonitrile
• Synonyms: 3-fluoro-4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-picolinonitrile
• CAS NO: 1383377-50-1
• Molecular Weight: 296.279
• Mol File: 1383377-50-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3-fluoro-4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-picolinonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-fluoro-4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-picolinonitrile(1383377-50-1)
• EPA Substance Registry System: 3-fluoro-4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-picolinonitrile(1383377-50-1)

Safety Data

• Hazardous Substances Data: 1383377-50-1(Hazardous Substances Data)

Upstream product

• 863605-35-0 3-(4'-fluorophenyl)-1-methylpyrazole 
• 154258-82-9 3-(4-fluorophenyl)-1H-pyrazole 
• 75175-77-8 3-(dimethylamino)-1-(4-fluorophenyl)prop-2-en-1-one 
• 403-42-9 1-(4-fluorophenyl)ethanone 
• 399-88-2 3-fluoro-4-methylpyridine 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 1383377-56-7 3-fluoro-4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)pyridine 
• 863605-34-9 4-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazole 
• 669066-35-7 3-fluoro-4-iodo-2-pyridinecarbonitrile 
• 1286230-78-1 3-(4-fluorophenyl)-1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 7677-24-9 trimethylsilyl cyanide 
• 1383377-58-9 3-fluoro-4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)pyridine 1-oxide 

Downstream Products

• 1383377-59-0 4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-6-methyl-5Hpyrrolo[3,4-b]pyridine-5,7(6H)-dione 
• 1383376-93-9 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one 
• 1383376-95-1 4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-6,7-dihydro-5Hpyrrolo[3,4-b]pyridin-5-one 
• 1383377-62-5 4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-5H-pyrrolo[3,4-b]pyridine-5,7(6H)-dione 
• 1383377-51-2 4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)pyridine-2,3-dicarbonitrile 
• 1383377-64-7 tert-butyl (2-((2-cyano-4-(3-(4-fluorophenyl)-1-methyl-1Hpyrazol-4-yl)pyridin-3-yl)oxy)ethyl)carbamate 
• 1383376-92-8 4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)furo[3,4-b]pyridin-5(7H)-one 
• 1383376-96-2 6-benzyl-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one 
• 1383377-63-6 6-benzyl-4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-5Hpyrrolo[3,4-b]pyridine-5,7(6H)-dione 
• 1383376-97-3 6-benzyl-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine 
• 1383376-98-4 9-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-2,3,4,5-tetrahydropyrido[2,3-f ][1,4]oxazepine 
• 1383377-66-9 9-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-3,4-dihydropyrido[2,3-f ][1,4]oxazepin-5(2H)-one 
• 1383377-67-0 4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-3-hydroxypicolinonitrile 
• 1383377-68-1 tert-butyl 2-(2-cyano-4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)pyridin-3-yloxy)propylcarbamate 

Relevant articles and documents

Synthesis of novel fluorophenylpyrazole-picolinamide derivatives and determination of their anticancer activity

A series of fluorophenylpyrazole-picolinamide derivatives were synthesized in high yields using a cross-coupling reaction catalyzed by in situ formed palladium-N-heterocyclic carbenes (Pd-NHCs). The synthesized novel derivatives were evaluated for in vitro anticancer activity against a panel of four human tumor cell lines, HeLa (cervical), A-549 (lung), MCF-7 (breast), and IMR-32 (neuroblastoma). Four compounds, 11c, 11e, 11j, and 11k, showed growth inhibition (low μM) comparable with the standard drug cisplatin, providing a preliminary structure–activity relationship for the series. The present procedure is operationally simple and works with a wide range of substrates and may thus be useful in further compound optimization.

Ligand-protein interactions of selective casein kinase 1δ inhibitors

Casein kinase 1δ (CK1δ) and 1ε (CK1ε) are believed to be necessary enzymes for the regulation of circadian rhythms in all mammals. On the basis of our previously published work demonstrating a CK1ε-preferring compound to be an ineffective circadian clock modulator, we have synthesized a series of pyrazole-substitued pyridine inhibitors, selective for the CK1δ isoform. Additionally, using structure-based drug design, we have been able to exploit differences in the hinge region between CK1δ and p38 to find selective inhibitors that have minimal p38 activity. The SAR, brain exposure, and the effect of these inhibitors on mouse circadian rhythms are described. The in vivo evaluation of these inhibitors demonstrates that selective inhibition of CK1δ at sufficient central exposure levels is capable of modulating circadian rhythms.